The Next Steps for Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
Data from a phase III trial were presented at a plenary session at the 2013 American Society of Clinical Oncology (ASCO) Meeting. The manuscript will be reviewed by the Gynecologic Oncology Group (GOG) publications committee, CTEP, and the NCI. Then, Tewari says, it will be reviewed by the journal chosen by the researchers.
Clinical Pearls
As for the regulatory aspects of the trial, Tewari says that he is unsure of the timeline. Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA.
- Data were presented at the 2013 ASCO Meeting
- Manuscripts will be reviewed by the GOG publications committee, CTEP, and NCI
- Genentech and Roche, the manufacturers of the molecule, will discuss the possibility of approval with the FDA
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
